The clinical case for psilocybin in treatment-resistant major depressive disorder rests on a small but striking body of evidence. In controlled settings, with trained therapists present, one or two doses have produced measurable and durable improvements in patients for whom conventional antidepressants had failed. A study published in the Journal of the American Medical Association in 2025 demonstrated that a single dose of LSD could ease anxiety and depression for months. The FDA has granted psilocybin breakthrough therapy designation — a category created to accelerate review of drugs intended for serious conditions where preliminary evidence suggests substantial improvement over existing treatments.
None of this is trivial. Nor is any of it sufficient to support what the executive order implies.
The distance between a breakthrough-therapy designation and proof of broad clinical safety is not a technicality. It is the entire point of the regulatory process the order seeks to accelerate.
The order, signed on 18 April in the Oval Office, does three things. It directs the FDA to issue priority review vouchers for psychedelic compounds with breakthrough designations. It allocates fifty million dollars in federal funds for further research, structured as matching funds for state-level programmes. And it instructs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic drugs under the Right to Try Act — legislation originally designed for terminally ill patients who had exhausted all approved options.
FDA Commissioner Marty Makary announced that three priority review vouchers would be issued the following week, with decisions expected by summer. The speed is notable. So is the fact that the FDA had already vetoed a fast-track approval for Compass Pathways’ psilocybin treatment earlier in 2026. What changed was not the evidence. What changed was the political environment.
The ibogaine question
The compound that received the most attention at the signing was ibogaine, a psychoactive substance derived from the West African iboga plant. It is the only psychedelic mentioned by name in the order. Joe Rogan, present at the signing, claimed that a text message to the president initiated the entire policy. The president joked about wanting some himself.
Ibogaine’s clinical profile is more complicated than the ceremony suggested. Nora Volkow, director of the National Institute on Drug Abuse, has flagged documented cardiac risks associated with the compound. Most existing research has been conducted outside the United States. It has not completed Phase I trials domestically, which raises a specific problem: the Right to Try Act typically requires that a drug has passed Phase I — the basic safety threshold — before patients may access it.
The executive order appears to direct federal agencies to find a way around this requirement. Whether that pathway can be established without weakening the safety standard is a question the order does not answer. Legal scholars at Harvard’s Petrie-Flom Center have noted that the president cannot compel rescheduling of a controlled substance by executive order alone, but can substantially influence enforcement priorities, budgets, and the pace of review.
What the evidence does and does not support
The honest summary is this: psilocybin has shown genuine promise in supervised clinical settings for a specific, difficult-to-treat condition. The trials have been small. The patients have been carefully screened — excluding, among others, those with a history of psychosis or certain cardiovascular conditions. The therapeutic context has been intensive: trained therapists, controlled environments, extensive follow-up.
What the evidence supports is further research, larger trials, and a rigorous path to potential approval. What it does not support is the implication — present in the framing, if not the text, of the order — that these compounds are ready for broad deployment.
Fourteen million American adults have a serious mental illness. The question is not whether new treatments are needed. The question is whether the pace of access should outrun the pace of evidence.
The Department of Veterans Affairs is now participating in at least five clinical trials of psychedelic compounds across sites in New York, California, and Oregon. The data from these trials — conducted under proper controls, with proper follow-up — will be the most important evidence produced in the next several years. The executive order does not fund these trials. It funds a separate research programme and accelerates a regulatory process that was already underway.
The five-year consequence
The institutional consequence of this order will be felt long after the news cycle moves on. If the Right to Try pathway is extended to compounds that have not completed Phase I trials, the precedent applies to every experimental compound, not only psychedelics. If executive action can direct the FDA to accelerate review timelines on a politically favourable class of drugs, the same mechanism is available for any drug any future administration chooses to promote.
The clinical researchers working on these compounds understand this. Several, speaking after the signing, praised the order while carefully noting that the fastest and safest path remains the FDA’s standard approval process. What they are saying, politely, is that the evidence should set the timeline — not the other way around.
The Association for Prescription Psychedelics called the order an ‘encouraging sign’ while emphasising that psychedelics under development are undergoing rigorous clinical trials. The Disabled American Veterans praised the intent while advocating for care delivered within the VA system, not outside it. The pattern is consistent: gratitude for the attention, caution about the method.
The concentrated view: the psychedelic evidence is real, limited, and early-stage. The executive order is fast, broad, and politically motivated. The gap between the two is where the patients live — and where the serious work remains to be done.
